Therapeutic opportunities within the DNA damage response

Gene Ontology: tool for the unification of biology

Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

Gephi: An Open Source Software for Exploring and Manipulating Networks

Bastian, M., Heymann, S., & Jacomy, M. (2009) · Proceedings of the International AAAI Conference on Web and Social Media · doi:10.1609/icwsm.v3i1.13937 · Cited by 11,675

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

The cancer genome atlas pan-cancer analysis project

The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092

Comprehensive molecular characterization of human colon and rectal cancer

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499

Integrated genomic analyses of ovarian carcinoma

Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078

Cytoscape 2.8: new features for data integration and network visualization

Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P., & Ideker, T. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq675 · Cited by 4,770

STRING v9.1: protein-protein interaction networks, with increased coverage and integration

Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1094 · Cited by 4,398

ChEMBL: a large-scale bioactivity database for drug discovery

Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382

Comprehensive genomic characterization of squamous cell lung cancers

The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994

Drug-like properties and the causes of poor solubility and poor permeability

Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,776

How many drug targets are there?

Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505

Comprehensive molecular characterization of clear cell renal cell carcinoma

The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485

A census of human cancer genes

Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184

Patterns of somatic mutation in human cancer genomes

Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143

Data, information, knowledge and principle: back to metabolism in KEGG

Kanehisa, M. I., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1076 · Cited by 3,103

Comprehensive molecular characterization of urothelial bladder carcinoma

Perou, C. M. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,922

Molecular mechanisms of cisplatin resistance

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278

The causes and consequences of genetic heterogeneity in cancer evolution

Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986

An Oncogene-Induced DNA Damage Model for Cancer Development

Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851

Reactome: a database of reactions, pathways and biological processes

Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Garapati, P., Gopinath, G., Jassal, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1018 · Cited by 1,751

The DNA Damage Response: Ten Years After

Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705

DNA repair pathways as targets for cancer therapy

Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666

The DNA damage response and cancer therapy

Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649

PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse

Hornbeck, P. V., Kornhauser, J. M., Tkachev, S., Zhang, B., Skrzypek, E., Murray, B. W., Latham, V. M., & Sullivan, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1122 · Cited by 1,636

The Concept of Synthetic Lethality in the Context of Anticancer Therapy

Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405

Biallelic Inactivation of BRCA2 in Fanconi Anemia

Howlett, N. G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., de Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. (2002) · Science · doi:10.1126/science.1073834 · Cited by 1,149

Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers

Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,107

DNA repair dysregulation from cancer driver to therapeutic target

Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051

The BioGRID interaction database: 2013 update

Chatr‐aryamontri, A., Breitkreutz, B., Heinicke, S., Boucher, L., Winter, A. G., Stark, C., Nixon, J., Ramage, L., Kolas, N. K., O’Donnell, L., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1158 · Cited by 1,021

EUKARYOTIC TRANSLESION SYNTHESIS DNA POLYMERASES: Specificity of Structure and Function

Prakash, S., Johnson, R. E., & Prakash, L. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133250 · Cited by 1,020

Temozolomide: Mechanisms of Action, Repair and Resistance

Zhang, J., Stevens, M. F. G., & Bradshaw, T. D. (2011) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 951

Cytoscape 2.8: new features for data integration and network

Smoot, E., Ono, K., Ruscheinski, J., Wang, P., & Ideker, T. E. (2011) · Cited by 791

Genetic instability and darwinian selection in tumours

Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01661-x · Cited by 747

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615

Regulation of DNA Damage Responses by Ubiquitin and SUMO

Jackson, S. P., & Durocher, D. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.017 · Cited by 601

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

Antoniou, A. C., Cunningham, A. P., Peto, J., Evans, D. G., Lalloo, F. I., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Southey, M. C., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604305 · Cited by 524

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 493

Mutational signatures: the patterns of somatic mutations hidden in cancer genomes

Alexandrov, L. B., & Stratton, M. R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.014 · Cited by 488

Replication and protection of telomeres

Verdun, R. E., & Karlseder, J. (2007) · Nature · doi:10.1038/nature05976 · Cited by 463

MEN and SIN: what's the difference?

Bardin, A. J., & Amon, A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099020 · Cited by 347

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

Barber, L. J., Sandhu, S. K., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 345

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

Turner, N. C., Lord, C. J., Iorns, E. J., Brough, R., Swift, S., Elliott, R. J. R., Rayter, S., Tutt, A. N. J., & Ashworth, A. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.61 · Cited by 329

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 312

Integrated analysis of germline and somatic variants in ovarian cancer

Kanchi, K., Johnson, K. J., Lu, C., McLellan, M. D., Leiserson, M. D. M., Wendl, M. C., Zhang, Q., Koboldt, D. C., Xie, M., Kandoth, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4156 · Cited by 308

NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling

Lindström, M. S. (2011) · Biochemistry Research International · doi:10.1155/2011/195209 · Cited by 306

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 303

A selective USP1–UAF1 inhibitor links deubiquitination to DNA damage responses

Liang, Q., Dexheimer, T. S., Zhang, P., Rosenthal, A. S., Villamil, M. A., You, C., Zhang, Q., Chen, J., Ott, C. A., Sun, H., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1455 · Cited by 264

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Bancroft, E. K., Page, E. C., Castro, E., Lilja, H. G., Vickers, A. J., Sjoberg, D. D., Assel, M. J., Foster, C. S., Mitchell, G., Drew, K., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.003 · Cited by 253

Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses

Kuhn, E., Wu, R., Guan, B., Wu, G., Zhang, J., Wang, Y., Song, L., Yuan, X., Wei, L., Roden, R. B. S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs345 · Cited by 249

Mapping the Cancer Genome

Collins, F. S., & Barker, A. D. (2007) · Scientific American · doi:10.1038/scientificamerican0307-50 · Cited by 231

Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair

Nakazawa, Y., Sasaki, K., Mitsutake, N., Matsuse, M., Shimada, M., Nardò, T., Takahashi, Y., Ohyama, K., Ito, K., Mishima, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2229 · Cited by 213

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

Martin, S. A., McCabe, N., Mullarkey, M. J., Cummins, R., Burgess, D. J., Nakabeppu, Y., Oka, S., Kay, E. W., Lord, C. J., & Ashworth, A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.046 · Cited by 205

USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.

Fan, Y.-H., Cheng, J., Vasudevan, S. A., Dou, J., Zhang, H., Patel, R. H., Ma, I. T., Rojas, Y., Zhao, Y., Yu, Y., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.400 · Cited by 199

DNA repair: From molecular mechanism to human disease

Friedberg, E. C., Aguilera, A., Gellert, M. F., Hanawalt, P. C., Hays, J. B., Lehmann, A. R., Lindahl, T. L., Lowndes, N. F., Sarasin, A. R., & Wood, R. D. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.005 · Cited by 193

Structural basis for recruitment of BRCA2 by PALB2

Oliver, A. W., Swift, S., Lord, C. J., Ashworth, A., & Pearl, L. H. (2009) · EMBO Reports · doi:10.1038/embor.2009.126 · Cited by 188

Structure-based druggability assessment — identifying suitable targets for small molecule therapeutics

Fauman, E. B., Rai, B. K., & Huang, E. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.020 · Cited by 183

Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies.

Collins, F. S., & Barker, A. D. (2007) · PubMed · Cited by 176

A Small Molecule Inhibitor of the BLM Helicase Modulates Chromosome Stability in Human Cells

Nguyen, G. H., Dexheimer, T. S., Rosenthal, A. S., Chu, W. K., Singh, D. K., Mosedale, G., Bachrati, C. Z., Schultz, L., Sakurai, M., Savitsky, P. A., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.10.016 · Cited by 169

Non-homologous DNA end joining.

Pastwa, E., & Błasiak, J. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3622 · Cited by 163

Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity

Nishi, R., Wijnhoven, P. W. G., le Sage, C., Tjeertes, J., Galanty, Y., Forment, J. V., Clague, M. J., Urbé, S., & Jackson, S. P. (2014) · Nature Cell Biology · doi:10.1038/ncb3028 · Cited by 153

canSAR: an updated cancer research and drug discovery knowledgebase

Tym, J. E., Mitsopoulos, C., Coker, E. A., Razaz, P., Schierz, A. C., Antolín, A. A., & Al‐Lazikani, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1030 · Cited by 136

Objective assessment of cancer genes for drug discovery

Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 133

Integrated genomic analyses of ovarian carcinoma

The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129

Smc5/6: a link between DNA repair and unidirectional replication?

Murray, J. M., & Carr, A. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2309 · Cited by 113

Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities

Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2431 · Cited by 108

Searching for synthetic lethality in cancer

Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J., & Ashworth, A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.009 · Cited by 107

SnapShot: DNA Mismatch Repair

Larrea, A. A., Lujan, S. A., & Kunkel, T. A. (2010) · Cell · doi:10.1016/j.cell.2010.05.002 · Cited by 106

Chromosome Segregation in Budding Yeast: Sister Chromatid Cohesion and Related Mechanisms

Marston, A. L. (2014) · Genetics · doi:10.1534/genetics.112.145144 · Cited by 104

The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase

Franchitto, A., Pichierri, P., Piergentili, R., Crescenzi, M., Bignami, M., & Palitti, F. (2003) · Oncogene · doi:10.1038/sj.onc.1206254 · Cited by 102

Familial pancreatic cancer: genetic advancesPreprint

Rustgi, A. K. (2014) · Genes & Development · doi:10.1101/gad.228452.113 · Cited by 101

Breast Cancer Proteins PALB2 and BRCA2 Stimulate Polymerase η in Recombination-Associated DNA Synthesis at Blocked Replication Forks

Buisson, R., Joshi, N., Pauty, J., Maity, R., Zhao, W., Coulombe, Y., Sung, P., & Masson, J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.009 · Cited by 95

Deubiquitylating Enzymes and DNA Damage Response Pathways

Jacq, X., Kemp, M. I., Martin, N. M. B., & Jackson, S. P. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9635-3 · Cited by 90

An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development

van Pel, D. M., Barrett, I. J., Shimizu, Y., Sajesh, B. V., Guppy, B. J., Pfeifer, T., McManus, K. J., & Hieter, P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003254 · Cited by 89

Polo-like kinase 1 as target for cancer therapy

Weiß, L., & Efferth, T. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-38 · Cited by 84

Aurora kinases in head and neck cancer

Mehra, R., Serebriiskii, I. G., Burtness, B. A., Astsaturov, I. A., & Golemis, E. A. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70128-1 · Cited by 74

canSAR: updated cancer research and drug discovery knowledgebase

Bulusu, K. C., Tym, J. E., Coker, E. A., Schierz, A. C., & Al‐Lazikani, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1182 · Cited by 74

DNA Repair in Mammalian Cells

Eker, A. P. M., Quayle, C., Chaves, I., & van der Horst, G. T. J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8735-0 · Cited by 72

Definition of the intermediates and mechanism of the anticancer drug bleomycin using nuclear resonance vibrational spectroscopy and related methods

Liu, L. V., Bell, C. B., Wong, S. D., Wilson, S. A., Kwak, Y., Chow, M. S., Zhao, J. Y., Hodgson, K. O., Hedman, B., & Solomon, E. I. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016323107 · Cited by 72

A Single-Nucleotide Substitution Mutator Phenotype Revealed by Exome Sequencing of Human Colon Adenomas

Nikolaev, S. I., Sotiriou, S. K., Pateras, I. S., Santoni, F. A., Sougioultzis, S., Edgren, H., Almusa, H., Robyr, D., Guipponi, M., Saarela, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3869 · Cited by 70

APRIN is a cell cycle specific BRCA2‐interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer

Brough, R., Bajrami, I., Vatcheva, R., Natrajan, R., Reis-Filho, J. S., Lord, C. J., & Ashworth, A. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.490 · Cited by 69

Cancer chromosomes going to POT1

Chang, S. S. (2013) · Nature Genetics · doi:10.1038/ng.2617 · Cited by 64

Targeting an Achilles’ heel of cancer with a WRN helicase inhibitor

Aggarwal, M., Banerjee, T., Sommers, J. A., & Brosh, R. M. (2013) · Cell Cycle · doi:10.4161/cc.26320 · Cited by 62

DNA ligases as therapeutic targets.

Tomkinson, A. E., Howes, T. R. L., & Wiest, N. E. (2013) · PubMed · Cited by 60

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology

Workman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 60

Complementary non-radioactive assays for investigation of human flap endonuclease 1 activity

Dorjsuren, D. G., Kim, D., Maloney, D. J., Wilson, D. M., & Simeonov, A. M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1082 · Cited by 55

Deubiquitinating Enzymes as Therapeutic Targets in Cancer

Lim, K., & Baek, K. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319220013 · Cited by 54

DNA End-Processing Enzyme Polynucleotide Kinase As a Potential Target in the Treatment of Cancer

Allinson, S. L. (2010) · Future Oncology · doi:10.2217/fon.10.40 · Cited by 54

The RSC and INO80 Chromatin-Remodeling Complexes in DNA Double-Strand Break Repair

Chambers, A. L., & Downs, J. A. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-387665-2.00009-2 · Cited by 51

MoKCa database—mutations of kinases in cancer

Richardson, C. J., Gao, Q., Mitsopoulous, C., Zvelebil, M., Pearl, L. H., & Pearl, F. M. G. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn832 · Cited by 51

Investigations of homologous recombination pathways and their regulation.

Daley, J. M., Kwon, Y., Niu, H., & Sung, P. (2013) · Europe PMC (PubMed Central) · Cited by 46

Analysis of the gene coding for the BRCA2‐Interacting protein PALB2 in hereditary prostate cancer

Tischkowitz, M. D., Sabbaghian, N., Ray, A. M., Lange, E. M., Foulkes, W. D., & Cooney, K. A. (2008) · The Prostate · doi:10.1002/pros.20729 · Cited by 41

Saccharomyces cerevisiaeGenetics Predicts Candidate Therapeutic Genetic Interactions at the Mammalian Replication Fork

van Pel, D. M., Stirling, P. C., Minaker, S. W., Sipahimalani, P., & Hieter, P. (2013) · G3 Genes Genomes Genetics · doi:10.1534/g3.112.004754 · Cited by 39

Amino Acid Asp181 of 5′-Flap Endonuclease 1 Is a Useful Target for Chemotherapeutic Development

Panda, H., Jaiswal, A. S., Corsino, P. E., Armas, M. L., Law, B. K., & Narayan, S. (2009) · Biochemistry · doi:10.1021/bi9010754 · Cited by 36

Building high-resolution synthetic lethal networks: a ‘Google map’ of the cancer cell

Paul, J., Templeton, S. D., Baharani, A., Freywald, A., & Vizeacoumar, F. J. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.09.009 · Cited by 34

Fanconi anemia: a signal transduction and DNA repair pathway.

Kupfer, G. M. (2013) · Europe PMC (PubMed Central) · Cited by 33

Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase

Mereniuk, T. R., Gendy, M. A. M. E., Mendes‐Pereira, A. M., Lord, C. J., Ghosh, S., Foley, E., Ashworth, A., & Weinfeld, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1093 · Cited by 30

Molecular Mechanism of Base Excision Repair of Uracil-containing DNA in Yeast Cell-free Extracts

Wang, Z., Wu, X., & Friedberg, E. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.24064 · Cited by 29

Development of a High-Throughput Fluorescence Polarization DNA Cleavage Assay for the Identification of FEN1 Inhibitors

McWhirter, C. L., Tonge, M. E., Plant, H., Hardern, I. M., Nissink, J. W. M., & Durant, S. T. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113476551 · Cited by 25

Deriving a Mutation Index of Carcinogenicity Using Protein Structure and Protein Interfaces

Espinosa, O., Mitsopoulos, K., Hakas, J., Pearl, F. M. G., & Zvelebil, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084598 · Cited by 22

Recessive cancer genes engage in negative genetic interactions with their functional paralogs.

D'Antonio, M., Guerra, R., Cereda, M., Marchesi, S., Montani, F., Nicassio, F., Fiore, P. D., & Ciccarelli, F. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.033 · Cited by 17

DNA Repair: Nucleotide excision–repair in the test tube

Jaspers, N. G. J., & Hoeijmakers, J. H. J. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00137-0 · Cited by 5

Pan-cancer analysis of whole genomes

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064

Targeting the DNA Damage Response in Cancer

O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,602

Cell cycle control in cancer

Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

Knijnenburg, T., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,145

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

Huang, R., & Zhou, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 1,015

Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response

Das, S., Camphausen, K. A., & Shankavaram, U. T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01136 · Cited by 14

Targeting the DNA damage response in cancer

Guffanti, F., Chiappa, M., & Damia, G. L. M. (2024) · MedComm · doi:10.1002/mco2.788 · Cited by 30

Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy

McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 35

DNA repair dysregulation from cancer driver to therapeutic target

Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051

Targeting the key players of DNA Repair Pathways as Cancer Therapeutics

Roy, R. M., Garimella, S. V., & Pandrangi, S. L. (2022) · Research Journal of Biotechnology · doi:10.25303/1705rjbt203210 · Cited by 4